Taking into account all relevant factors, Exelixis, Inc. (NASDAQ:EXEL) scores 24% Buy on the technical side. The share price is also flashing a Buy from the Barchart TrendSpotter trading system. Investors starting out on a short-term path of investing should know that short terms indicators for EXEL averaged 50% Buy with an average daily trading volume over the past 20 days at 3318116 shares. Those using medium-term investment strategies, the shares have overall a 0.5% Sell signal while the 50-day average daily volume remained almost 3051697 shares. It’s also important to note that the stock, whose average daily volume over the 100 days as of this piece was 2865521 shares, is signaling50% Buy for long term investors.
The stock is lingering around the initial support level of $19.81. After this, the following support is at the zone of $19.23. Up until the time the EXEL stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 70.27 on the daily chart, and this may be a cause for concern. In case the price goes below $19.23 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $20.86 level may cause a pull-back move approaching $21.33 mark.
Exelixis, Inc. (EXEL) is most likely going to rise 17.86 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $35 as 12-month high price target. This represents a whopping 71.23 percent increase from the current trading price of shares. The 52-week median price target given by the analysts is $23, which means a return possibility of 12.52 percent in comparison with the closing price of the stock of $20.44 in recent trading session. The lowest price set for the stock is $19 which is just above -7.05 percent from EXEL share’s price at the end of session.
Let’s take a glimpse at some insider activity at Exelixis, Inc. (NASDAQ:EXEL) and observe the pattern. The earliest insider trade happened on 01/08/2020. MORRISSEY MICHAEL parted with a total of 25 thousand shares of the firm at average share price of $18.85. The total amount for the sale was set at $471.25 thousand. On completing this exchange, the President and CEO account balance was 425.84 thousand shares. The stock grew 6.79 percent from that insider sale. On 01/07/2020, Garber Alan M, Director, did a sale of 86.96 thousand shares at a price of $18.01 per share. This got rid of 1.57 million shares from the insider’s fortune and the stock experienced a 11.77 percent rally in price since the news became public. This exchange saw 61.33 thousand shares get out from the Director account. On 01/07/2020, Pres, Prod Dev & Med Aff & CMO Schwab Gisela recorded a sale transaction valued at $898 thousand. The sale at $17.96 a share has eliminated 50 thousand shares from the insider’s portfolio position. Meanwhile, shares price witnessed 12.08 percent increase since the transaction reporting date. The company insider is left with 340 thousand shares remaining in the account. MORRISSEY MICHAEL, who works as President and CEO at the company, performed a sale of 25 thousand shares in a transaction worth $437.25 thousand. The disposal recorded on 01/02/2020 was priced at $17.49 per share. The stock price soared 15.09 percent since the transaction. MORRISSEY MICHAEL currently holds a stake of 425.84 thousand in EXEL stock which is worth $8.7 million after the insider selling.
In the recent trading session, Exelixis, Inc. (NASDAQ:EXEL) shares gained 0.22% or 0.04 points to reach at $20.44 with a thin trading volume of 1.078 million shares. It opened the trading session at $19.73, the shares rose to $20.75 and dropped to $19.7, the range by which the price of stock traded the whole session. The company now has a market cap of $6.3 billion and currently has 308.99 million outstanding shares. Exelixis, Inc. (EXEL) stock has accumulated 14.45 percent of market value in 21 trading days.
Stock analysts at SunTrust, assumed coverage of shares of Exelixis, Inc. (NASDAQ:EXEL) with Buy recommendation, according to their opinion released on January 13. Analysts at Morgan Stanley issued an upgrade for the stock to Equal-Weight from previous rating of Underweight, in a research note that dated back to March 18.
EXEL stock’s trailing 3-year beta is 1.9, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was $1.96 share in the trailing 52 weeks. The stock’s value surged 15.75 percent year to date (YTD) compared to a decline of -15.2 percent in 52 week’s period. The firm’s shares are still trading -19.24 percent below its 1-year high of $25.31 and 36.09 percent up from 52-week low of $15.02. The average consensus ranking on the company is 2, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
Exelixis, Inc. (EXEL) shares are trading at a P/E ratio of 9.36 times earnings posted in the trailing 12 months. The industry EXEL deals with has an average P/E of 25.19. Its P/B ratio is standing at 3.6X compared to the 11.59 industry average. It is additionally sporting a 5.62 on the Price-to-Sales ratio, compared to the industry’s P/S average of 2.83. Exelixis, Inc. has a 96.9% gross profit margin, with its operating margin around 42.2%. Alongside this, the company’s net profit margin currently stands at 64%.
Past records have indicated that shares in Exelixis, Inc. declined on 21 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of EXEL’s Q4 earnings on March 03. Analysts are predicting revenue to climb 4.6 percent to $239M in the financial fourth quarter, while EPS will soar by about -86.09 percent to $0.16 per share. In the last quarter, it’s earnings of $0.25 per share came better than the $0.23273, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $228.6M, topping the $188.44M analysts had expected. Earnings are seen to rise by 346.3 percent this year, -2.23 percent in the coming year and the trend continues by 46 percent every year in the next 5 years.